21:13 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Athera begins Phase IIa trial of PC-mAb for arterial inflammation

Athera Biotechnologies AB (Stockholm, Sweden) began a Phase IIa trial of once-monthly IV PC-mAb to treat arterial inflammation in patients with elevated levels of lipoprotein(a) (LPA) . The double-blind, placebo-controlled, European trial's primary endpoint is...
19:53 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Athera raises SEK57M

In late August, cardiovascular company Athera Biotechnologies AB (Stockholm, Sweden) raised SEK57 million ($7.2 million) in a financing. Current investors The Foundation for Baltic and East European Studies, Industrifonden and Linc AB were joined by...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Athera, Boehringer Ingelheim deal

Athera said Boehringer declined to exercise its exclusive, 2013 option to PC-mAb , a human mAb against phosphorylcholine that is in Phase I testing to treat patients with cardiovascular disease at an increased risk for...
07:00 , May 26, 2014 |  BioCentury  |  Emerging Company Profile

Annexin: Attenuating vascular inflammation

Annexin Pharmaceuticals AB is developing an annexin A5 protein to help stop disease progression and prevent limb amputation in peripheral arterial occlusive disease. The protein has therapeutic benefits including anti-inflammatory, antithrombotic and anti-atherosclerotic activity. Current...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Athera board of directors update

Athera Biotechnologies AB , Stockholm, Sweden   Business: Cardiovascular   Appointed: Gunnar Olsson as chairman, formerly head of the global cardiovascular and gastrointestinal disease team at AstraZeneca plc ; he replaces Per Sjoberg, who resigned...
07:00 , Jul 11, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Last month's public-private partnership with the highest total funding was the launch of the Global Health Innovative Technology Fund , an infectious disease initiative that plans to disperse $100 million over 5 years. On the...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Athera, Boehringer Ingelheim deal

Boehringer received an exclusive option from Athera to PC-mAb , a human preclinical mAb against phosphorylcholine (PC) , to treat patients with cardiovascular disease at an increased risk for secondary events and death. Athera will...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Athera cardiovascular news

Athera received a grant from the EU's Seventh Framework Program (FP7) to develop the company's human antibody PC-mAb to treat patients with an increased risk of atherosclerosis-related cardiovascular events and death. Specifically, FP7 will provide...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Company News

Athera, Dyax deal

The companies will partner to discover and develop antibodies against phosphorylcholine (PC) to prevent or treat cardiovascular diseases such as atherosclerosis. Dyax will use its antibody libraries to generate human mAbs, and Athera will provide...